We evaluated a new sequential HRT regimen (Climen‐Schering) consisting of a combination of estradiol valerate (2 mg, days 1‐11) and cyproterone acetate (CPA: 1 mg) plus estradiol valerate (2 mg, days 12‐21) followed by a 7‐day interval with no drug intake. The interesting aspect of this regimen is the use of CPA. a strong progestogen with antiandrogenic properties. For this reason, CPA is expected not to counteract the favourable estrogen impact on lipids.
A New HRT Regimen Using Estradiol Valerate and Cyproterone Acetate: Impact on Lipid Metabolism
OMODEI, Umberto;
1995-01-01
Abstract
We evaluated a new sequential HRT regimen (Climen‐Schering) consisting of a combination of estradiol valerate (2 mg, days 1‐11) and cyproterone acetate (CPA: 1 mg) plus estradiol valerate (2 mg, days 12‐21) followed by a 7‐day interval with no drug intake. The interesting aspect of this regimen is the use of CPA. a strong progestogen with antiandrogenic properties. For this reason, CPA is expected not to counteract the favourable estrogen impact on lipids.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
